TriSalus Life Sciences Posts 60% Q4 Revenue Surge, Raises $46M in Offering
TriSalus Life Sciences posted Q4 2025 revenue of $13.2 million, up 60% year-over-year, and full-year revenue of $45.2 million, up 53%. The company raised $46 million in an oversubscribed public offering and expanded its product portfolio from two to seven offerings while reporting a $3.3 million operating loss.
1. Q4 and Full-Year 2025 Results
TriSalus Life Sciences reported Q4 2025 revenue of $13.2 million, a 60% increase year-over-year, and full-year revenue of $45.2 million, up 53% over 2024. Despite top-line growth, the company recorded a $3.3 million operating loss and a basic and diluted loss per share of $1.84.
2. $46M Public Offering
The company completed a $46 million public offering that was more than two times oversubscribed, strengthening its cash position and providing financial flexibility for clinical and commercial initiatives.
3. Product Portfolio Expansion
TriSalus expanded its differentiated offerings from two to seven products, doubling its commercial organization and pairing clinical specialists with sales representatives to enhance market penetration and clinical support.
4. Clinical Pipeline and Growth Outlook
Updated clinical data for the Nela Tolemad program has been pushed to the second half of 2026. Foundational studies on the PEDD platform are underway, with management forecasting continued liver application revenue in 2026 and meaningful non-liver progress in thyroid and uterine fibroid programs by year-end.